HOTH vs. HEPA, GHSI, BIOR, GDTC, BFRG, FBRX, INDP, CPIX, JAGX, and NRBO
Should you be buying Hoth Therapeutics stock or one of its competitors? The main competitors of Hoth Therapeutics include Hepion Pharmaceuticals (HEPA), Guardion Health Sciences (GHSI), Biora Therapeutics (BIOR), CytoMed Therapeutics (GDTC), Bullfrog AI (BFRG), Forte Biosciences (FBRX), Indaptus Therapeutics (INDP), Cumberland Pharmaceuticals (CPIX), Jaguar Health (JAGX), and NeuroBo Pharmaceuticals (NRBO). These companies are all part of the "pharmaceutical preparations" industry.
Hepion Pharmaceuticals (NASDAQ:HEPA) and Hoth Therapeutics (NASDAQ:HOTH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, community ranking, media sentiment and analyst recommendations.
In the previous week, Hepion Pharmaceuticals had 1 more articles in the media than Hoth Therapeutics. MarketBeat recorded 2 mentions for Hepion Pharmaceuticals and 1 mentions for Hoth Therapeutics. Hepion Pharmaceuticals' average media sentiment score of 1.87 beat Hoth Therapeutics' score of 1.59 indicating that Hoth Therapeutics is being referred to more favorably in the news media.
Hoth Therapeutics has a consensus target price of $4.00, indicating a potential upside of 241.88%. Given Hepion Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Hoth Therapeutics is more favorable than Hepion Pharmaceuticals.
Hoth Therapeutics received 44 more outperform votes than Hepion Pharmaceuticals when rated by MarketBeat users. However, 67.74% of users gave Hepion Pharmaceuticals an outperform vote while only 63.11% of users gave Hoth Therapeutics an outperform vote.
17.2% of Hepion Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Hoth Therapeutics shares are owned by institutional investors. 2.0% of Hepion Pharmaceuticals shares are owned by company insiders. Comparatively, 3.3% of Hoth Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Hepion Pharmaceuticals has a beta of 1.72, suggesting that its stock price is 72% more volatile than the S&P 500. Comparatively, Hoth Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.
Hepion Pharmaceuticals' return on equity of -83.03% beat Hoth Therapeutics' return on equity.
Summary
Hoth Therapeutics beats Hepion Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
Get Hoth Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HOTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hoth Therapeutics Competitors List
Related Companies and Tools
